磷酸二酯酶5在心力衰竭中作用的研究进展

doi:10.16352/j.issn.1001-6325.2024.05.0724

基础医学与临床 ›› 2024, Vol. 44 ›› Issue (5): 724-728.doi: 10.16352/j.issn.1001-6325.2024.05.0724

磷酸二酯酶5在心力衰竭中作用的研究进展

杨洋, 张雅茸, 杨红琴, 王婧, 赵红梅^*

中国医学科学院基础医学研究所北京协和医学院基础学院病理生理学系,北京 100005

收稿日期:2024-02-01 修回日期:2024-03-19 出版日期:2024-05-05 发布日期:2024-04-23
通讯作者: ^*hongmeizhao@ibms.pumc.edu.cn
基金资助:
国家自然科学基金(82270403);国家重点研发计划(2019YFA0801804, 2019YFA081703)

Research progress of phosphodiesterase 5 in heart failure

YANG Yang, ZHANG Yarong, YANG Hongqin, WANG Jing, ZHAO Hongmei^*

Department of Pathophysiology, Institute of Basic Medical Sciences CAMS, School of Basic Medicine PUMC, Beijing 100005, China

Received:2024-02-01 Revised:2024-03-19 Online:2024-05-05 Published:2024-04-23
Contact: ^*hongmeizhao@ibms.pumc.edu.cn

摘要/Abstract

摘要： 磷酸二酯酶5(PDE5)是环磷酸鸟苷(cGMP)特异性水解酶,是由一氧化氮(NO)激活的可溶性鸟苷酸环化酶(sGC)靶向cGMP产生的。PDE5催化cGMP中磷酸二酯键的水解,从而将cGMP转化为无活性的5′-GMP形式,cGMP-PKG轴功能障碍将引起心脏重塑,是心力衰竭(HF)的主要原因之一。但PDE5抑制剂治疗心力衰竭的临床疗效存在争议。本文总结了近年来PDE5在心力衰竭中的作用机制和研究进展,对未来临床应用PDE5靶向治疗心力衰竭具有重要的指导意义。

关键词: 心力衰竭, 磷酸二酯酶5, 磷酸二酯酶抑制剂, 环磷酸鸟苷

Abstract: Phosphodiesterase 5 (PDE5), a cyclic guanosine monophosphate (cGMP)-specific hydrolase, is targets cGMP produced by soluble guanosine cyclase (sGC) that is activated by nitric oxide (NO). It catalyzes the hydrolysis of the phosphodiester bond in cGMP and converts cGMP to the inactive 5′-GMP form. The cGMP-PKG axis dysfunction is one of the main causes of heart failure (HF) and causes cardiac remodeling. However, the clinical efficacy of PDE5 inhibitors in the treatment of heart failure is controversial. This paper summarizes the mechanism and research progress of PDE5 in heart failure in recent years, which has important significance for the clinical application of PDE5 in heart failure.

Key words: heart failure, phosphodiesterase 5, phosphodiesterase inhibitor, cyclic guanosine monophosphate

中图分类号:

R363

杨洋, 张雅茸, 杨红琴, 王婧, 赵红梅. 磷酸二酯酶5在心力衰竭中作用的研究进展[J]. 基础医学与临床, 2024, 44(5): 724-728.

YANG Yang, ZHANG Yarong, YANG Hongqin, WANG Jing, ZHAO Hongmei. Research progress of phosphodiesterase 5 in heart failure[J]. Basic & Clinical Medicine, 2024, 44(5): 724-728.

参考文献

[1] Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the american college of cardiology/american heart association joint committee on clinical practice guidelines[J]. Circulation, 2022, 145: e895-e1032.
[2] Preedy MEJ. Cardiac cyclic nucleotide phosphodiester-ases: roles and therapeutic potential in heart failure[J]. Cardiovasc Drugs Ther, 2020, 34: 401-417.
[3] Roy S, Kloner RA, Salloum FN, et al. Cardiac effects of phosphodiesterase-5 inhibitors: efficacy and safety[J]. Cardiovasc Drugs Ther, 2023, 37: 793-806.
[4] Dang TA, Schunkert H, Kessler T. cGMP signaling in cardiovascular diseases: linking genotype and phenotype[J]. J Cardiovasc Pharmacol, 2020, 75: 516-525.
[5] Emdin M, Aimo A, Castiglione V, et al. Targeting cyclic guanosine monophosphate to treat heart failure review topic of the week[J]. J Am Coll Cardiol, 2020, 76: 1795-1807.
[6] Huang CK, Chen BY, Guo A, et al. Sildenafil amelio-rates left ventricular T-tubule remodeling in a pressure overload-induced murine heart failure model[J]. Acta Pharmacol Sin, 2016, 37: 473-482.
[7] Rademaker MT, Scott NJA, Charles CJ, et al. Combined inhibition of phosphodiesterase-5 and -9 in experimental heart failure[J]. JACC. Heart failure, 2024, 12: 100-113.
[8] Mora AG, Andrade DR, Janussi SC, et al. Tadalafil treatment improves cardiac, renal and lower urinary tract dysfunctions in rats with heart failure[J]. Life Sci, 2022, 289: 120237. doi:10.1016/j.lfs.2021.120237.
[9] 刘晓晴, 杨建钦, 王栩林, 等. 新型磷酸二酯酶5抑制剂CPD1对异丙肾上腺素诱导心肌肥厚大鼠心脏的保护作用[J]. 中国药理学通报, 2022, 38: 1388-1394.
[10] Zhu G, Ueda K, Hashimoto M, et al. The mitochondrial regulator pgc1α is induced by cGMP-PKG signaling and mediates the protective effects of phosphodiesterase 5 inhibition in heart failure[J]. FEBS Lett, 2022, 596: 17-28.
[11] Pokreisz P, Vandenwijngaert S, Bito V, et al. Ventricular phosphodiesterase-5 expression is increased in patients with advanced heart failure and contributes to adverse ventricular remodeling after myocardial infarction in mice[J]. Circulation, 2009, 119: 408-416.
[12] Zhang ML, Takimoto E, Hsu S, et al. Myocardial remodeling is controlled by myocyte-targeted gene regulation of phosphodiesterase type 5[J]. J Am Coll Cardiol, 2010, 56: 2021-2030.
[13] Patrucco E, Domes K, Sbroggió M, et al. Roles of cGMP-dependent protein kinase I (cGKI) and PDE5 in the regulation of Ang Ⅱ-induced cardiac hypertrophy and fibrosis[J]. Proc Natl Acad Sci U S A, 2014, 111: 12925-12929.
[14] Feil R, Lehners M, Stehle D, et al. Visualising and understanding cgmp signals in the cardiovascular system[J]. Br J Pharmacol, 2022, 179: 2394-2412.
[15] Straubinger J, Schöttle V, Bork N, et al. Sildenafil does not prevent heart hypertrophy and fibrosis induced by cardiomyocyte angiotensin Ⅱ type 1 receptor signaling[J]. J Pharmacol Exp Ther, 2015, 354: 406-416.
[16] Lukowski R, Rybalkin SD, Loga F, et al. Cardiac hypertrophy is not amplified by deletion of cGMP-dependent protein kinase I in cardiomyocytes[J]. Proc Natl Acad Sci U S A, 2010, 107: 5646-5651.
[17] Redfield MM, Chen HH, Borlaug BA, et al. Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction a randomized clinical trial[J]. JAMA, 2013, 309: 1268-1277.
[18] Belyavskiy E, Ovchinnikov A, Potekhina A, et al. Phosphodiesterase 5 inhibitor sildenafil in patients with heart failure with preserved ejection fraction and combined pre- and postcapillary pulmonary hypertension: a randomized open-label pilot study[J]. BMC Cardiovasc Disord, 2020, 20: 408. doi:10.1186/s12872-020-01671-2.
[19] Mátyás C, Németh BT, Oláh A, et al. Prevention of the development of heart failure with preserved ejection fraction by the phosphodiesterase-5A inhibitor vardenafil in rats with type 2 diabetes[J]. Eur J Heart Fail, 2017, 19: 326-336.
[20] Guazzi M, Vicenzi M, Arena R, et al. PDE5 inhibition with sildenafil improves left ventricular diastolic function, cardiac geometry, and clinical status in patients with stable systolic heart failure results of a 1-year, prospective, randomized, placebo-controlled study[J]. Circ Heart Fail, 2011, 4: 8-17.
[21] Kim KH, Kim HK, Hwang IC, et al. PDE5 5 inhibition with udenafil improves left ventricular systolic/diastolic functions and exercise capacity in patients with chronic heart failure with reduced ejection fraction; a 12-week, randomized, double-blind, placebo-controlled trial[J]. Am Heart J, 2015, 169: 813-822.
[22] Cooper TJ, Cleland JGF, Guazzi M, et al. Effects of sildenafil on symptoms and exercise capacity for heart failure with reduced ejection fraction and pulmonary hypertension (the silHF study): a randomized placebo-controlled multicentre trial[J]. Eur J Heart Fail, 2022, 24: 1239-1248.
[23] Monzón-Herrera R, Listorti F, Vensentini N, et al. phosphodiesterase 5 inhibitors for the treatment of heart failure: a systematic review and meta-analysis[J]. Arch Cardiol Mex, 2024. doi:10.24875/ACM.23000209.

磷酸二酯酶5在心力衰竭中作用的研究进展

Research progress of phosphodiesterase 5 in heart failure

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	高超, 张润菡, 王伟, 赵曼婷, 焦艳, 李喆. 青蒿琥酯调节cGAS-STING信号通路对抑郁症模型小鼠神经炎性反应的影响[J]. 基础医学与临床, 2024, 44(8): 1126-1132.
[2]	胡川丽, 贺晓松, 赵江, 李华. 基于机器学习算法的心力衰竭预测模型[J]. 基础医学与临床, 2024, 44(6): 845-852.
[3]	柴亚如, 邓玉婷, 戴红艳, 管军. Klotho在心力衰竭中作用的研究进展[J]. 基础医学与临床, 2023, 43(6): 998-1002.
[4]	王英臣, 孙立群. 二肽基肽酶Ⅲ在治疗脓毒症中的应用进展[J]. 基础医学与临床, 2023, 43(1): 196-199.
[5]	樊佳赛, 杜艺菲, 许佳颖, 陈思臻, 高永桧, 任景怡. 基于中医证候和机器学习构建慢性心力衰竭中西医结合预后模型[J]. 基础医学与临床, 2022, 42(8): 1169-1175.
[6]	刘峰宇, 韩薇. 心肌细胞钙稳态失调在心力衰竭中作用的研究进展[J]. 基础医学与临床, 2022, 42(3): 502-506.
[7]	王放, 董哲, 孙艺红, 任景怡, 李菁, 周益锋, 郑金刚. 影响非缺血性心力衰竭患者心肌纤维化的因素分析[J]. 基础医学与临床, 2021, 41(3): 346-351.
[8]	张志敏, 苟丽沙, 马丽群, 任可, 路军, 魏星, 李慧杰, 周圣华. 达格列净降低心力衰竭大鼠心肌内质网应激并缓解左室重构[J]. 基础医学与临床, 2021, 41(12): 1742-1748.
[9]	刘颖娴, 宋彦君, 陈未, 林雪, 赖晋智, 黎婧怡, 吴炜. 非缺血性心力衰竭患者应用伊伐布雷定的有效性与安全性评价[J]. 基础医学与临床, 2021, 41(11): 1637-1642.
[10]	胡欢李萍程晓曙. 线粒体融合-分裂与心力衰竭[J]. 基础医学与临床, 2018, 38(4): 553-556.
[11]	徐建平杨保卫. Ghrelin对心衰恶液质的治疗作用*[J]. 基础医学与临床, 2012, 32(1): 102-105.
[12]	李英莲李维善. 青海地区老年人心力衰竭患者血浆BNP水平变化与临床观察分析[J]. 基础医学与临床, 2010, 30(2): 205-205.
[13]	杨华沈珠军. 脂肪来源细胞在缺血性心脏病中的应用[J]. 基础医学与临床, 2010, 30(11): 1226-1229.
[14]	孔一慧曹荣元张莉刘玉冰李悦李为民. β3肾上腺素能受体激动剂和抑制剂对心衰大鼠心室MMP2和9表达的影响[J]. 基础医学与临床, 2010, 30(11): 1177-1183.
[15]	刘洪岩张金国谭洪勇. 慢性心力衰竭患者血浆APN水平与BNP、TNF-α、IR相关性[J]. 基础医学与临床, 2010, 30(10): 1098-1099.